About Putative E3 ubiquitin-protein ligase UBR7
Putative E3 ubiquitin-protein ligase UBR7 (UBR7) is a protein
from Homo sapiens identified by UniProt accession
Q8N806, 425 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Putative E3 ubiquitin-protein ligase UBR7 |
| UniProt accession | Q8N806 |
| Gene | UBR7 |
| Organism | Homo sapiens |
| Length | 425 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (41)
Diseases linked to this target (Open Targets).
- Li-Campeau syndrome · score 0.60
- hypothyroidism · score 0.47
- Intellectual disability · score 0.46
- epilepsy · score 0.46
- complex neurodevelopmental disorder · score 0.37
- autosomal recessive non-syndromic intellectual disability · score 0.37
- Intellectual disability, mild · score 0.33
- Global developmental delay · score 0.11
- neoplasm · score 0.08
- hepatocellular carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N806-F1 | alphafold | PREDICTED | 75.36 | — |
Amino-acid sequence (425 residues)
MAGAEGAAGR QSELEPVVSL VDVLEEDEEL ENEACAVLGG SDSEKCSYSQ GSVKRQALYA CSTCTPEGEE PAGICLACSY ECHGSHKLFE LYTKRNFRCD CGNSKFKNLE CKLLPDKAKV NSGNKYNDNF FGLYCICKRP YPDPEDEIPD EMIQCVVCED WFHGRHLGAI PPESGDFQEM VCQACMKRCS FLWAYAAQLA VTKISTEDDG LVRNIDGIGD QEVIKPENGE HQDSTLKEDV PEQGKDDVRE VKVEQNSEPC AGSSSESDLQ TVFKNESLNA ESKSGCKLQE LKAKQLIKKD TATYWPLNWR SKLCTCQDCM KMYGDLDVLF LTDEYDTVLA YENKGKIAQA TDRSDPLMDT LSSMNRVQQV ELICEYNDLK TELKDYLKRF ADEGTVVKRE DIQQFFEEFQ SKKRRRVDGM QYYCS
Explore Putative E3 ubiquitin-protein ligase UBR7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets